Medical needs bone regeneration

For a number of bone degenerative diseases the existing treatment is insufficient. Especially in cases of larger defects in combination with age related healing impairments, diabetes or radiation therapy. The "golden standard" for these so-called critical sized defects is autologous bone transplantation. This therapy is however associated with drawbacks such as:

  • limited availability of donor bonebroken bone
  • risk of donor site morbidity
  • post-operative pain at donor site
  • time investment of surgeon

In the past 20 years alternatives for autologous bone transplantation have been introduced. So far with an overall lack of success because of problems like:

  • local inflammation after implant surgery
  • infection around the area of resorption
  • insufficient bone/implant mechanical strength
  • lack of vascularisation of the large bone defects

Regeneration of critical bone defects requires bio-mimetic and bio-active materials to trigger the required biological events for full bone repair. The optimal therapeutic approach will depend on the specific conditions of the patient and on the specific disease situation.

Bio-Inspire will train a next generation of leading scientists in Europe. In a 4-year program a technology platform will be developed to solve a broad range of bone therapeutic needs. The technology platform is based on a new collagen I recombinant peptide. This biomaterial scaffold has unique neo-vascularisation and bio-mineralisation properties, and will be used as:

  • bio-mimetic mineralised scaffold
  • local delivery system for growth factors
  • delivery system for (autologous) cells

Partners

Bone Therapeutics SA

Erasmus Medical Center

Fraunhofer Institute

Fujifilm Manufacturing B.V.

Medicyte

ISTEC - CNR

University of Bologna

Marie Curie Actions

Logo Marie Curieeu logo
The research leading to these results has received funding from the European Union Seventh Framework Programme FP7/2007-2013 under grant agreement n° 607051.